快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点

财经网2020-02-13

财经网产经讯据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

毋所事事
2020-02-14
毋所事事
利好？

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2011750324?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","is_english":false,"pubTime":"2020-02-13 10:30","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2011750324","market":"us","top_or_hot":-1,"title":"快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点","media":"财经网","content":"<div>\n<p>财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-02-13 10:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b><strong>财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b","article_id":"2011750324","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2011750324","pubTimestamp":1581561016,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"MRK":"默沙东"},"translate_title":"Mercadon: Keytruda Combined with Chemotherapy Reaches Primary Endpoint of Progression-Free Survival","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.6},"content_text":"财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合化疗的一线治疗，与单独化疗相比，PFS出现了具有统计学意义和临床意义的改善。根据DMC的建议，试验将继续进行，以评价另一个双重主要终点总生存期(OS)。默沙东表示，将与监管机构沟通这次试验的数据，并且在即将到来的医学会议上公布研究结果。目前，默沙东正在开展关于Keytruda治疗乳腺癌的多项内部和外部合作的临床开发，包括三项正在进行的TNBC注册研究（KEYNOTE-355，KEYNOTE-242和KEYNOTE-522）。Merck研究实验室总裁 Roger M. Perlmutter 博士表示：“这是个非常令人鼓舞的结果，Keytruda联合化疗作为治疗转移性TNBC的一线疗法（本次KEYNOTE-355试验），以及作为新辅助疗法（KEYNOTE-522 试验），均表现出积极的结果。”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":917182709,"gmtCreate":1581644856601,"gmtModify":1704344867060,"author":{"id":"3450003023906401","authorId":"3450003023906401","name":"毋所事事","avatar":"https://static.tigerbbs.com/dd9aaf594337ff049eb0049203d0c26e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3450003023906401","authorIdStr":"3450003023906401"},"htmlText":"利好？","listText":"利好？","text":"利好？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/917182709","repostId":2011750324,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2011750324"}